Kolon TissueGene
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kolon TissueGene is a biotech company focused on developing cell and gene therapy treatments, primarily targeting joint diseases such as osteoarthritis.
Its products are aimed at patients and are administered through medical professionals in clinical or hospital settings. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and operates as a clinical-stage biopharmaceutical business.
Summary is AI-generated and may contain errors · figures from DART filings
Kolon TissueGene in five facts
What does Kolon TissueGene do?
Kolon TissueGene is a biotech company focused on developing cell and gene therapy treatments, primarily targeting joint diseases such as osteoarthritis.
Where is Kolon TissueGene listed and in which sector?
Kolon TissueGene (Korean name: 코오롱티슈진) trades under KRX code 950160 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kolon TissueGene?
Its market capitalisation was US$1B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kolon TissueGene's latest annual revenue and operating profit?
For fiscal year 2025, Kolon TissueGene reported revenue of US$2.7K, an operating loss of US$11.8K and a net loss of US$102.2K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 2.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of CEOSep 18
- Report on large shareholdings (5% rule) (standard)Sep 18
- DisclosureSep 16
- [Amended] DisclosureSep 15
- Material event report (rights offering)
Kolon TissueGene disclosed a private placement (third-party allotment) to raise US$40.6M, about 4.1% of its market value.
Capital raise · Mar 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kolon TissueGene reported separate results for FY2025: revenue of US$3.54M (+1.7% year on year), an operating loss of US$15.3M and a net loss of US$132M.
Earnings · Feb 11